Results 141 to 150 of about 12,625 (176)

Nirmatrelvir+ritonavir

Reactions Weekly
  +5 more sources

Molnupiravir/nirmatrelvir+ritonavir

Reactions Weekly, 2023
  +4 more sources

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?

Biomedicine and Pharmacotherapy, 2023
Seyed Mohammadreza Hashemian, Amirhossein Sheida, Mohammad Taghizadieh   +2 more
exaly  

Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)

Clinical Infectious Diseases, 2023
Rockib Uddin, Caitlin Marino, James P Flynn   +2 more
exaly  

Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs

Clinical Infectious Diseases, 2023
Louis D Saravolatz, Sharma Mamta
exaly  

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study

Vaccines, 2022
Ivan Gentile, Riccardo Scotto, Nicola Schiano Moriello   +2 more
exaly  

Real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID‐19: A retrospective cohort study

Journal of Medical Virology, 2023
Guangtong Deng, Huiyan Sun, Yating Dian   +2 more
exaly  

Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

International Journal of Antimicrobial Agents, 2023
Jon Salmanton-Garcia, Francesco Marchesi, Iker Falces-Romero   +2 more
exaly  

Dexamethasone/nirmatrelvir+ritonavir

Reactions Weekly, 2023
openaire   +1 more source

Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19

Open Forum Infectious Diseases, 2022
Sarah Lim, Christopher J Tignanelli, Nicolas Hoertel   +2 more
exaly